ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.

CADTH » Search All Products » Health Technology Assessment » Recombinant Activated Factor VII for Prevention of Bleeding Unrelated to Hemophilia: Clinical and Economic Systematic Review

Recombinant Activated Factor VII for Prevention of Bleeding Unrelated to Hemophilia: Clinical and Economic Systematic Review

CADTH’s health technology assessment report examines the clinical efficacy and cost-effectiveness of off-label use of recombinant activated factor VII (rFVIIa), an agent currently approved to control bleeding in patients with either hemophilia A or B and clotting factor inhibitors.  

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries